XML 37 R9.htm IDEA: XBRL DOCUMENT v3.20.1
Overview of Business
3 Months Ended
Mar. 31, 2020
Basis of Presentation [Abstract]  
Overview of Business

1.    Overview of Business

Intercept Pharmaceuticals, Inc. (the “Company”) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (“PBC”) and nonalcoholic steatohepatitis (“NASH”). The Company currently has one marketed product, Ocaliva (obeticholic acid or “OCA”). Founded in 2002 in New York, the Company has operations in the United States, Europe and Canada.